(Q33494941)

27 July 2017

title

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study (English)

1 reference

27 July 2017

1 reference

1 reference

Betticher DC

1

1 reference

27 July 2017

Anderson H

2

1 reference

27 July 2017

Ranson M

3

1 reference

27 July 2017

Meely K

4

1 reference

27 July 2017

Oster W

5

1 reference

27 July 2017

Thatcher N

6

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

British Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

72

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

1551-1555

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1995.546

27 July 2017

exact match

0 references

cites work

Phase I study of WR-2721 and carboplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Carboplatin: the clinical spectrum to date

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

New protective agents for bone marrow in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

The current status of toxicity protectants in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034079

Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice

31 October 2018

1 reference

12 December 2020

Human pharmacokinetics of WR-2721

1 reference

12 December 2020

The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin

1 reference

12 December 2020

Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival

1 reference

12 December 2020

WR-2721 and hypocalcemia

1 reference

12 December 2020

Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1995.546

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference